The difference in cancer detection

Cxbladder - The difference in cancer detection

Cxbladder is a non-invasive genomic urine test that quickly and accurately detects or rules out bladder cancer. The tests works at a molecular level, measuring five biomarker genes to detect the presence or absence of bladder cancer1, and comes as a suite of three product variations, each optimised for a different point in the patient journey.

Cxbladder Triage

If a patient presents with blood in their urine (haematuria), a physician may wish to quickly rule out bladder cancer. Cxbladder Triage analyses the gene expression of urine-based biomarkers alongside information on known bladder cancer risk factors like age, gender and smoking history to rule out patients with a low risk of having the disease.3

Cxbladder Triage provides accurate results and reassurance that can reduce the need for further invasive procedures like a cystoscopy. 

Cxbladder Detect

If a doctor suspects bladder cancer, they may use Cxbladder Detect in combination with other tests and procedures to inform the diagnosis. Cxbladder Detect can be used as an adjunct to cystoscopy or as a substitute for other urine-based tests or imaging procedures.

In detecting and quantifying signs of cancer at the molecular level, Cxbladder Detect outperforms other urine-based tests, making it an ideal choice for bladder cancer testing in patients presenting with significant symptoms.2

Cxbladder Monitor

In cases where a patient has had bladder cancer in the past and is surveilling for recurrence, a doctor may suggest Cxbladder Monitor as a non-invasive and easy-to-use test to rule out the return of bladder cancer. Compared to invasive and often uncomfortable procedures like the cystoscopy, Cxbladder Monitor provides accurate results with an easy-to-collect urine sample.4 





  • A suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with haematuria, or surveilling for bladder cancer recurrence
  • Facilitates early detection of bladder cancer2 and helps rule out bladder cancer-free patients 3, 4
  • Effective adjunct to cystoscopy
  • Can be used to replace other urine-based tests or replace the need for CT / IVP in some instances
  • Easy to use - a complete sampling system is provided for collection and shipment of the patient's urine to our laboratory

Cxbladder is available in the following countries

  • Australia – Through Pacific Edge PTY Australia
  • New Zealand – Through Pacific Edge Diagnostics NZ
  • Singapore - Through Pacific Edge Diagnostics Singapore
  • United States – Through Pacific Edge Diagnostics USA

For further information on Cxbladder, please visit:

1 Holyoake et al: Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder, Clin Cancer Res 2008; 14(3): 742-749

2 O'Sullivan et. al: A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria, J Urol 2012; 188: 741-747

3 Kavalieris et al: A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma, BMC Urology 2015; 15:23

4 Kavalieris L, O’Sullivan PJ, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017; 197:6, 1419-1426


Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).